PTEN and cancer: Compared with ATP-competitive inhibitors that show efficacy only against cancer cell lines with Akt mutations, allosteric inhibitors display broader anticancer activity as compounds of this type are potent against cancer cell lines with PI3KCA mutations or loss of phosphatase and tensin homologue (PTEN) activity [16].